Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
A loss of -1.890% shows a downward development for Pacira Pharmaceuticals.
Pacira Pharmaceuticals is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
As a result the target price of 29 € shows a positive potential of 39.42% compared to the current price of 20.8 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -1.890% | 0.980% | 15.084% | 15.084% | 11.351% | -52.752% | -56.170% |
| Twist Bioscience Corp | 0.550% | 6.382% | 3.901% | -44.483% | -40.586% | 8.963% | -76.778% |
| Rockwell Medical Inc. | 0.820% | -3.933% | -10.886% | -61.409% | -61.830% | -16.359% | -93.005% |
| Vericel Corp. | 0.000% | -1.852% | -4.790% | -40.000% | -41.651% | 42.537% | 48.114% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat